Consumers who bought certain generic prescription drugs between May 2009 and December 2019 have until March 8, 2027 to file under settlements that 48 attorneys general reached with generic drug manufacturers. The deal stems from allegations that manufacturers fixed prices and rigged bids on more than 100 generic drugs, with some prices rising as much as 1,000 percent. The claim window is open now, about five months out.
What the 48 attorneys general are alleging
New York Attorney General Letitia James announced the largest piece of the deal on October 1, 2026, a settlement with Sandoz. Her office describes a coalition of 48 attorneys general, New York plus 47 others, that accused the industry of “a broad, coordinated, and systematic conspiracy to fix prices, avoid competition, and rig bids for more than 100 different generic drugs.” According to the same release, executives coordinated at industry social events and by phone, email and text.
The settlements are agreements, not findings after trial, and the allegations are the states’ claims. What is settled is the money and the process for paying it out. James said in the release that “generic drug price increases make it harder for working families throughout New York to afford the medications they need.”
The practical question for a household is whether a given purchase falls inside the window and on the list. A prescription filled in 2008 or in 2020 sits outside it; one filled in 2014 may sit inside it. Pharmacy printouts, insurer explanation-of-benefits statements and old receipts are the records that can place a purchase on a date, and the claim form is where the list of covered drugs gets matched against what was actually bought.
Readers who bought generics during those years and are unsure whether a given purchase counts face the same sorting job: matching purchase dates to the notice, then keeping a record of what was filed. The Settlement & Refund Recovery System, an independent paid guide, includes the four-date rule for reading a settlement notice and a step-by-step filing walkthrough aimed at exactly that.
Read the generic drug settlement notice with the four-date rule →
The Sandoz figure and what it covers
The number most often quoted from the announcement, $320,560,180, is easy to misread. It is the principal Sandoz will pay over the next seven years. With interest, the New York release puts the total at $400 million. That amount belongs to the Sandoz agreement alone and is not a single pool for every consumer claim. Other manufacturers settled separately, and the California Attorney General’s office lists them in its own notice.
Because Sandoz pays over seven years, the money does not arrive in one lump. The releases do not publish a per-person payment figure, and neither says when distributions begin, so the amount any individual receives is not something either office states.
The window: May 2009 through December 2019
California Attorney General Rob Bonta’s office says eligible purchases fall between May 2009 and December 2019, and that the deadline to submit a claim is March 8, 2027. The notice covers consumers who bought any generic drug on the settlement list during that period. Bonta urged anyone who purchased an eligible medication to take a few minutes to check eligibility and submit a claim.
The New York release applies the same window to New Yorkers who bought the listed drugs. The states’ notices point to one administrator site, AGGenericDrugs.com, which carries the list of covered drugs, along with a toll-free line at 1-866-290-0182 and an email address for questions. Both attorney general releases name that site as the place to file, though the administrator’s domain was not loading properly on a certificate check, so the attorney general releases remain the reachable official statement of the deadline and window.
Why the deadline sits so far out
A March 2027 close leaves months for consumers to find records from a decade or more ago. The attorneys general framed the notice as an effort to reach people who bought generics for chronic conditions over many years, a group that may have refilled the same prescriptions dozens of times. A claim submitted well before the deadline also leaves time to fix a missing date or a mismatched drug name if the administrator asks.
The deadline is the one date the releases state outright. Anyone who files should treat it as the date the claim must be in, not the date a payment arrives, and should keep a copy of whatever confirmation the administrator issues.
Filing a generic drug claim before March 8, 2027
The free route starts with the attorneys general. The California Attorney General’s notice and the New York Attorney General’s release both direct consumers to AGGenericDrugs.com, to the toll-free line at 1-866-290-0182 and to a mailed claim form. A claim can be filed without paying anyone.
Before opening the form, it helps to gather the drug names, approximate fill dates between May 2009 and December 2019, and any pharmacy or insurance records that show them. The California release does not specify what proof the claim form requires, so the form itself is the final word on that. Compare each prescription against the settlement’s drug list rather than assuming a generic is covered.
The step most likely to trip a filer is a record gap: a pharmacy that changed hands, an insurer that no longer exists or a statement that was discarded. The administrator’s phone line is the place to ask what substitutes are accepted, and the March 8, 2027 date set by the attorneys general is the one that does not move.
Readers who want the filing laid out in order can use The Settlement & Refund Recovery System, an independent paid kit that includes a step-by-step filing walkthrough and a 5-tab Excel tracker with a claim log and payment tracker for the settlements still open.
Click here to get The Settlement & Refund Recovery System for the generic drug claim →
This article was produced with AI assistance and reviewed by The Financial Wire’s editorial team.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
